Results 291 to 300 of about 9,288,830 (350)
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer. [PDF]
Grinshpun A +14 more
europepmc +1 more source
Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience. [PDF]
Hussein NE +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Lancet Oncology, 2021
BACKGROUND Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer.
E. Mayer +43 more
semanticscholar +1 more source
BACKGROUND Palbociclib added to endocrine therapy improves progression-free survival in hormone-receptor-positive, HER2-negative, metastatic breast cancer.
E. Mayer +43 more
semanticscholar +1 more source
Journal of Clinical Oncology, 2022
PURPOSE To our knowledge, WSG-ADAPT-HR+/HER2– (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET ...
U. Nitz +26 more
semanticscholar +1 more source
PURPOSE To our knowledge, WSG-ADAPT-HR+/HER2– (ClinicalTrials.gov identifier: NCT01779206; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET ...
U. Nitz +26 more
semanticscholar +1 more source
Hematology/Oncology Clinics of North America, 1989
Endocrine therapy is still a mainstay in the treatment of metastatic breast cancer. It has been observed that about one third of women with metastatic breast cancer will respond to endocrine therapy. This response rate is surprisingly consistent for a wide variety of endocrine approaches, with a few exceptions, such as the use of corticosteroids ...
K I, Pritchard, D J, Sutherland
openaire +2 more sources
Endocrine therapy is still a mainstay in the treatment of metastatic breast cancer. It has been observed that about one third of women with metastatic breast cancer will respond to endocrine therapy. This response rate is surprisingly consistent for a wide variety of endocrine approaches, with a few exceptions, such as the use of corticosteroids ...
K I, Pritchard, D J, Sutherland
openaire +2 more sources
Postgraduate Medicine, 1971
Endocrine therapy has produced dramatic results in some situations in obstetrics and gynecology and is beneficial in amenorrhea of unknown origin, in some menopausal patients, and in some cases of endometriosis. It also seems to retard progression of metastasis in patients who have had surgery or radiotherapy in breast cancer.
openaire +2 more sources
Endocrine therapy has produced dramatic results in some situations in obstetrics and gynecology and is beneficial in amenorrhea of unknown origin, in some menopausal patients, and in some cases of endometriosis. It also seems to retard progression of metastasis in patients who have had surgery or radiotherapy in breast cancer.
openaire +2 more sources
Journal of Clinical Oncology, 2019
PURPOSE To update the ASCO clinical practice guideline on adjuvant endocrine therapy based on emerging data about the optimal duration of aromatase inhibitor (AI) treatment.
H. Burstein +11 more
semanticscholar +1 more source
PURPOSE To update the ASCO clinical practice guideline on adjuvant endocrine therapy based on emerging data about the optimal duration of aromatase inhibitor (AI) treatment.
H. Burstein +11 more
semanticscholar +1 more source

